Abstract
The deposition of beta-amyloid (Aβ) aggregates in the brain, accompanied by impaired cognitive function, is a characteristic feature of Alzheimer’s disease (AD). An important role in this process is played by vascular disorders, in particular, a disturbance of the blood-brain barrier (BBB). The BBB controls the entry of Aβ from plasma to the brain via the receptor for advanced glycation end products (RAGE) and the removal of brain-derived Aβ via the low-density lipoprotein receptor-related protein (LRP1). The balance between the input of Aβ to the brain from the periphery and its output is disturbed during AD. Aβ changes the redox-status of BBB cells, which in turn changes the functioning of mitochondria and disrupts the barrier function of endothelial cells by affecting tight junction proteins. Aβ oligomers have the greatest toxic effect on BBB cells, and oligomers are most rapidly transferred by transcytosis from the brain side of the BBB to the blood side. Both the cytotoxic effect of Aβ and the impairment of barrier function are partly due to the interaction of Aβ monomers and oligomers with membrane-bound RAGE. AD therapies based on the disruption of this interaction or the creation of decoys for Aβ are being developed. The question of the transfer of various Aβ isoforms through the BBB is important, since it can influence the development of AD. It is shown that the rate of input of Aβ40 and Aβ42 from the blood into the brain is different. The actual question of the transfer of pathogenic Aβ isoforms with post-translational modifications or mutations through the BBB still remains open.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable
Code of availability
Not applicable
References
Abbott NJ (2013) Blood-brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 36:437–449. https://doi.org/10.1007/s10545-013-9608-0
Agarwal R, Shukla GS (1999) Potential role of cerebral glutathione in the maintenance of blood-brain barrier integrity in rat. Neurochem Res 24:1507–1514. https://doi.org/10.1023/a:1021191729865
Ahmad AA, Gassmann M, Ogunshola OO (2009) Maintaining blood-brain barrier integrity: pericytes perform better than astrocytes during prolonged oxygen deprivation. J Cell Physiol 218:612–622. https://doi.org/10.1002/jcp.21638
Ahmad AA, Taboada CB, Gassmann M, Ogunshola OO (2011) Astrocytes and pericytes differentially modulate blood-brain barrier characteristics during development and hypoxic insult. J Cereb Blood Flow Metab 31:693–705. https://doi.org/10.1038/jcbfm.2010.148
Ainscow EK, Brand MD (1999) Top-down control analysis of ATP turnover, glycolysis and oxidative phosphorylation in rat hepatocytes. Eur J Biochem 263:671–685. https://doi.org/10.1046/j.1432-1327.1999.00534.x
Alberdi E, Sanchez-Gomez MV, Cavaliere F et al (2010) Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47:264–272. https://doi.org/10.1016/j.ceca.2009.12.010
Aleardi AM, Benard G, Augereau O, Malgat M, Talbot JC, Mazat JP, Letellier T, Dachary-Prigent J, Solaini GC, Rossignol R (2005) Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation,reactive oxygen species production, and cytochrome c release. J Bioenerg Biomembr 37:207–225. https://doi.org/10.1007/s10863-005-6631-3
Askarova S, Yang X, Sheng W et al (2011) Role of Aβ-receptor for advanced glycation endproducts interaction in oxidative stress and cytosolic phospholipase A2 activation in astrocytes and cerebral endothelial cells. Neuroscience 199:375–385. https://doi.org/10.1016/j.neuroscience.2011.09.038
Banks WA (2012) Drug delivery to the brain in Alzheimer’s disease: consideration of the blood–brain barrier. Adv Drug Delivery Rev 64:629–639. https://doi.org/10.1016/j.addr.2011.12.005
Barykin EP, Petrushanko IY, Burnysheva KM et al (2016) Isomerization of Asp7 increases the toxic effects of amyloid β and its phosphorylated form in SH-SY5Y neuroblastoma cells. Mol Biol (Mosk) 50:863–869. https://doi.org/10.7868/S0026898416050037
Barykin EP, Mitkevich VA, Kozin SA, Makarov AA (2017) Amyloid β modification: a key to the sporadic Alzheimer’s disease? Front Genet 8:58. https://doi.org/10.3389/fgene.2017.00058
Barykin EP, Petrushanko IY, Kozin SA et al (2018) Phosphorylation of the amyloid-beta peptide inhibits zinc-dependent aggregation, prevents Na,K-ATPase inhibition, and reduces cerebral plaque deposition. Front Mol Neurosci 11:302. https://doi.org/10.3389/fnmol.2018.00302
Barykin EP, Garifulina AI, Kruykova EV et al (2019) Isomerization of Asp7 in beta-amyloid enhances inhibition of the α7 nicotinic receptor and promotes neurotoxicity. Cells 8:E771. https://doi.org/10.3390/cells8080771
Bell RD, Zlokovic BV (2009) Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer’s disease. Acta Neuropathol 118:103–113. https://doi.org/10.1007/s00401-009-0522-3
Bell RD, Sagare AP, Friedman AE et al (2007) Transport pathways for clearance of human Alzheimer’s amyloid β-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27:909–918. https://doi.org/10.1038/sj.jcbfm.9600419
Bongarzone S, Savickas V, Luzi F, Gee AD (2017) Targeting the receptor for advanced glycation endproducts (RAGE): a medicinal chemistry perspective. J Med Chem 60:7213–7232. https://doi.org/10.1021/acs.jmedchem.7b00058
Brown GC, Lakin-Thomas PL, Brand MD (1990) Control of respiration and oxidative phosphorylation in isolated rat liver cells. Eur J Biochem 192:355–362. https://doi.org/10.1111/j.1432-1033.1990.tb19234.x
Butterfield DA, Bader Lange ML, Sultana R (2010) Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer’s disease. Biochim Biophys Acta 1801:924–929. https://doi.org/10.1016/j.bbalip.2010.02.005
Cai C, Dai X, Zhu Y et al (2016) A specific RAGE-binding peptide biopanning from phage display random peptide library that ameliorates symptoms in amyloid β peptide-mediated neuronal disorder. Appl Microbiol Biotechnol 100:825–835. https://doi.org/10.1007/s00253-015-7001-7
Cai Z, Qiao P-F, Wan C-Q et al (2018) Role of Blood-Brain Barrier in Alzheimer's Disease. J Alzheimers Dis 63(4):1223–1234. https://doi.org/10.3233/JAD-180098
Camilleri A, Zarb C, Caruana M et al (2013) Mitochondrial membrane permeabilisation by amyloid aggregates and protection by polyphenols. Biochim Biophys Acta 1828:2532–2543. https://doi.org/10.1016/j.bbamem.2013.06.026
Campisi M, Shin Y, Osaki T et al (2018) 3D self-organized microvascular model of the human blood-brain barrier with endothelial cells, pericytes and astrocytes. Biomaterials 180:117–129. https://doi.org/10.1016/j.biomaterials.2018.07.014
Candela P, Gosselet F, Saint-Pol J et al (2010) Apical-to-basolateral transport of amyloid-β peptides through blood-brain barrier cells is mediated by the receptor for advanced glycation end-products and is restricted by P-glycoprotein. J Alzheimers Dis 22:849–859. https://doi.org/10.3233/JAD-2010-100462
Cha M-Y, Han S-H, Son SM et al (2012) Mitochondria-specific accumulation of amyloid β induces mitochondrial dysfunction leading to apoptotic cell death. PLoS One 7:e34929. https://doi.org/10.1371/journal.pone.0034929
Chaney MO, Stine WB, Kokjohn TA et al (2005) RAGE and amyloid beta interactions: atomic force microscopy and molecular modeling. Biochim Biophys Acta 1741:199–205. https://doi.org/10.1016/j.bbadis.2005.03.014
Chellappa RC, Lukose B, Rani P (2021) Correction: G82S RAGE polymorphism influences amyloid-RAGE interactions relevant in Alzheimer’s disease pathology. PLoS One 16:e0248252. https://doi.org/10.1371/journal.pone.0248252
Cheng C, Tsuneyama K, Kominami R et al (2005) Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs. Mod Pathol 18:1385–1396. https://doi.org/10.1038/modpathol.3800450
Cho D-H, Nakamura T, Fang J et al (2009) S-nitrosylation of Drp1 mediates beta-amyloid-related mitochondrial fission and neuronal injury. Science 324:102–105. https://doi.org/10.1126/science.1171091
Cole SL, Vassar R (2007) The Alzheimer’s disease beta-secretase enzyme, BACE1. Mol Neurodegener 2:22. https://doi.org/10.1186/1750-1326-2-22
Cuevas E, Rosas-Hernandez H, Burks SM et al (2019) Amyloid Beta 25-35 induces blood-brain barrier disruption in vitro. Metab Brain Dis 34:1365–1374. https://doi.org/10.1007/s11011-019-00447-8
Czupalla CJ, Liebner S, Devraj K (2014) In vitro models of the blood-brain barrier. Methods Mol Biol 1135:415–437. https://doi.org/10.1007/978-1-4939-0320-7_34
Dattilo BM, Fritz G, Leclerc E et al (2007) The extracellular region of the receptor for advanced glycation end products is composed of two independent structural units. Biochemistry 46:6957–6970. https://doi.org/10.1021/bi7003735
Deane R, Du Yan S, Submamaryan RK et al (2003) RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9:907–913. https://doi.org/10.1038/nm890
Deane R, Singh I, Sagare AP et al (2012) A multimodal RAGE-specific inhibitor reduces amyloid β–mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122:1377–1392. https://doi.org/10.1172/JCI58642
Deniaud A, Sharaf el dein O, Maillier E et al (2008) Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis. Oncogene 27:285–299. https://doi.org/10.1038/sj.onc.1210638
Denton RM, Randle PJ, Martin BR (1972) Stimulation by calcium ions of pyruvate dehydrogenase phosphate phosphatase. Biochem J 128:161–163. https://doi.org/10.1042/bj1280161
DeStefano JG, Jamieson JJ, Linville RM, Searson PC (2018) Benchmarking in vitro tissue-engineered blood-brain barrier models. Fluids Barriers CNS 15:32. https://doi.org/10.1186/s12987-018-0117-2
Dietrich M, Antequera D, Pascual C et al (2014) Alzheimer’s disease-like impaired cognition in endothelial-specific megalin-null mice. J Alzheimer’s Dis 39:711–717. https://doi.org/10.3233/JAD-131604
Ding Q, Keller JN (2005) Evaluation of rage isoforms, ligands, and signaling in the brain. Biochim Biophys Acta 1746:18–27. https://doi.org/10.1016/j.bbamcr.2005.08.006
Drummond GR, Selemidis S, Griendling KK, Sobey CG (2011) Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10:453–471. https://doi.org/10.1038/nrd3403
Düzel E, Ziegler G, Berron D et al (2022) Amyloid pathology but not APOE E4 status is permissive for tau-related hippocampal dysfunction. Brain 145:1473–1485. https://doi.org/10.1093/brain/awab405
Dyer RR, Ford KI, Robinson RAS (2019) The roles of S-nitrosylation and S-glutathionylation in Alzheimer’s disease. Methods Enzymol 626:499–538. https://doi.org/10.1016/bs.mie.2019.08.004
Eckert A, Hauptmann S, Scherping I et al (2008) Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J Mol Med (Berl) 86:1255–1267. https://doi.org/10.1007/s00109-008-0391-6
Eigenmann DE, Xue G, Kim KS et al (2013) Comparative study of four immortalized human brain capillary endothelial cell lines, hCMEC/D3, hBMEC, TY10, and BB19, and optimization of culture conditions, for an in vitro blood–brain barrier model for drug permeability studies. Fluids Barriers CNS 10:33. https://doi.org/10.1186/2045-8118-10-33
Elbert DL, Patterson BW, Bateman RJ (2015) Analysis of a compartmental model of amyloid beta production, irreversible loss and exchange in humans. Math. Biosci. 261:48–61. https://doi.org/10.1016/j.mbs.2014.11.004
Elbert DL, Patterson BW, Lucey BP et al (2022) Importance of CSF-based Aβ clearance with age in humans increases with declining efficacy of blood-brain barrier/proteolytic pathways. Commun Biol 5:98. https://doi.org/10.1038/s42003-022-03037-0
Emanuele E, D’Angelo A, Tomaino C et al (2005) Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch Neurol 62:1734–1736. https://doi.org/10.1001/archneur.62.11.1734
Solis E Jr, Hascup KN, Hascup ER (2020) Alzheimer's disease: the link between amyloid-β and neurovascular dysfunction. J Alzheimers Dis 76(4):1179–1198. https://doi.org/10.3233/JAD-200473
Fanning AS, Jameson BJ, Jesaitis LA, Anderson JM (1998) The tight junction protein ZO-1 establishes a link between the transmembrane protein occludin and the actin cytoskeleton. J Biol Chem 273:29745–29753. https://doi.org/10.1074/jbc.273.45.29745
Fonseca ACRG, Ferreiro E, Oliveira CR et al (2013) Activation of the endoplasmic reticulum stress response by the amyloid-beta 1-40 peptide in brain endothelial cells. Biochim Biophys Acta 1832:2191–2203. https://doi.org/10.1016/j.bbadis.2013.08.007
Gilbert BJ (2013) The role of amyloid β in the pathogenesis of Alzheimer’s disease. J Clin Pathol 66:362–366. https://doi.org/10.1136/jclinpath-2013-201515
Giri R, Shen Y, Stins M et al (2000) beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol. 279(6):1772–1781. https://doi.org/10.1152/ajpcell.2000.279.6.C1772
Gospodarska E, Kupniewska-Kozak A, Goch G, Dadlez M (2011) Binding studies of truncated variants of the Aβ peptide to the V-domain of the RAGE receptor reveal Aβ residues responsible for binding. Biochim Biophys Acta 1814:592–609. https://doi.org/10.1016/j.bbapap.2011.02.011
Greenberg SM, Bacskai BJ, Hernandez-Guillamon M et al (2020) Cerebral amyloid angiopathy and Alzheimer disease—one peptide, two pathways. Nat Rev Neurol 16(1):30–42. https://doi.org/10.1038/s41582-019-0281-2
Guglielmotto M, Monteleone D, Boido M et al (2012) Aβ1-42-mediated down-regulation of Uch-L1 is dependent on NF-κB activation and impaired BACE1 lysosomal degradation. Aging Cell 11:834–844. https://doi.org/10.1111/j.1474-9726.2012.00854.x
Han BH, Zhou M-L, Johnson AW et al (2015) Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice. Proc Natl Acad Sci U S A 112:E881–E890. https://doi.org/10.1073/pnas.1414930112
Hansford RG (1972) Some properties of pyruvate and 2-oxoglutarate oxidation by blowfly flight-muscle mitochondria. Biochem J 127(1):271–283. https://doi.org/10.1042/bj1270271
Hansford RG, Chappell JB (1967) The effect of Ca2+ on the oxidation of glycerol phosphate by blowfly flight-muscle mitochondria. Biochem Biophys Res Commun 27:686–692. https://doi.org/10.1016/s0006-291x(67)80090-1
Hong Y, Shen C, Yin Q, Sun M et al (2016) Effects of RAGE-specific inhibitor FPS-ZM1 on amyloid-β metabolism and AGEs-induced inflammation and oxidative stress in rat hippocampus. Neurochem Res 41(5):1192-1199. https://doi.org/10.1007/s11064-015-1814-8
Hori O, Brett J, Slattery T et al (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270:25752–25761. https://doi.org/10.1074/jbc.270.43.25752
Hou Y, Ghosh P, Wan R et al (2014) Permeability transition pore-mediated mitochondrial superoxide flashes mediate an early inhibitory effect of amyloid beta1-42 on neural progenitor cell proliferation. Neurobiol Aging 35:975–989. https://doi.org/10.1016/j.neurobiolaging.2013.11.002
Hudson BI, Carter AM, Harja E et al (2008) Identification, classification, and expression of RAGE gene splice variants. FASEB J 22:1572–1580. https://doi.org/10.1096/fj.07-9909com
Jarosz-Griffiths HH, Noble E, Rushworth JV, Hooper NM (2016) Amyloid-β receptors: the good, the bad, and the prion protein. J Biol Chem 291:3174–3183. https://doi.org/10.1074/jbc.R115.702704
Johnson NA, Jahng G-H, Weiner MW et al (2005) Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 234:851–859. https://doi.org/10.1148/radiol.2343040197
Jucker M, Walker LC (2018) Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat Neurosci 21:1341–1349. https://doi.org/10.1038/s41593-018-0238-6
Kadry H, Noorani B, Cucullo L (2020) A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity. Fluids Barriers CNS 17:69. https://doi.org/10.1186/s12987-020-00230-3
Kagan BL, Hirakura Y, Azimov R et al (2002) The channel hypothesis of Alzheimer’s disease: current status. Peptides 23:1311–1315. https://doi.org/10.1016/s0196-9781(02)00067-0
Kaminsky YG, Kosenko EA (2008) Effects of amyloid-beta peptides on hydrogen peroxide-metabolizing enzymes in rat brain in vivo. Free Radic Res 42:564–573. https://doi.org/10.1080/10715760802159057
Kaminsky YG, Tikhonova LA, Kosenko EA (2015) Critical analysis of Alzheimer’s amyloid-beta toxicity to mitochondria. Front Biosci (Landmark Ed) 20:173–197. https://doi.org/10.2741/4304
Kamynina AV, Esteras N, Koroev DO et al (2018) Synthetic fragments of receptor for advanced glycation end products bind beta-amyloid 1-40 and protect primary brain cells from beta-amyloid toxicity. Front Neurosci 12:681. https://doi.org/10.3389/fnins.2018.00681
Kawahara M, Kuroda Y, Arispe N, Rojas E (2000) Alzheimer’s beta-amyloid, human islet amylin, and prion protein fragment evoke intracellular free calcium elevations by a common mechanism in a hypothalamic GnRH neuronal cell line. J Biol Chem 275:14077–14083. https://doi.org/10.1074/jbc.275.19.14077
Kheiri G, Dolatshahi M, Rahmani F, Rezaei N (2018) Role of p38/MAPKs in Alzheimer’s disease:implications for amyloid beta toxicity targetedtherapy. Rev Neurosci 30(1):9–30. https://doi.org/10.1515/revneuro-2018-0008
Koch M, Chitayat S, Dattilo BM et al (2010) Structural basis for ligand recognition and activation of RAGE. Structure 18:1342–1352. https://doi.org/10.1016/j.str.2010.05.017
Kong W, Zhang J, Gao W et al (2013) β-amyloid protein up-regulates the expression of the receptor for advanced glycation end products by increasing ROS production. Nan Fang Yi Ke Da Xue Xue Bao 33:1132–1136
Kook S-Y, Hong HS, Moon M et al (2012) Aβ1-42-RAGE interaction disrupts tight junctions of the blood-brain barrier via Ca2+-calcineurin signaling. J Neurosci 32:8845–8854. https://doi.org/10.1523/JNEUROSCI.6102-11.2012
Kozin SA, Barykin EP, Telegin GB et al (2018) Intravenously injected amyloid-β peptide with isomerized Asp7 and phosphorylated Ser8 residues inhibits cerebral β-amyloidosis in AβPP/PS1 transgenic mice model of Alzheimer’s disease. Front Neurosci 12:518. https://doi.org/10.3389/fnins.2018.00518
Kozin SA, Cheglakov IB, Ovsepyan AA et al (2013) Peripherally applied synthetic peptide isoAsp7-Aβ(1-42) triggers cerebral β-amyloidosis. Neurotox Res 24:370–376. https://doi.org/10.1007/s12640-013-9399-y
Kozin SA, Mitkevich VA, Makarov AA (2016) Amyloid-β containing isoaspartate 7 as potential biomarker and drug target in Alzheimer’s disease. Mendeleev Commun 26:269–275. https://doi.org/10.1016/j.mencom.2016.07.001
Kroemer G, Reed JC (2000) Mitochondrial control of cell death. Nat Med 6:513–519. https://doi.org/10.1038/74994
Kwak Y-D, Wang R, Li JJ et al (2011) Differential regulation of BACE1 expression by oxidative and nitrosative signals. Mol Neurodegener 6:17. https://doi.org/10.1186/1750-1326-6-17
LaFerla FM (2002) Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat Rev Neurosci 3:862–872. https://doi.org/10.1038/nrn960
LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nat Rev Neurosci 8:499–509. https://doi.org/10.1038/nrn2168
Lakunina VA, Petrushanko IY, Burnysheva KM et al (2017) Alzheimer’s disease Aβ42 peptide induces an increase in Na,K-ATPase glutathionylation. Dokl Biochem Biophys 473:114–117. https://doi.org/10.1134/S1607672917020077
Lao K, Zhang R, Luan J et al (2021) Therapeutic strategies targeting amyloid-β receptors and transporters in Alzheimer’s disease. J Alzheimers Dis 79:1429–1442. https://doi.org/10.3233/JAD-200851
Lovell MA, Markesbery WR (2007) Oxidative damage in mild cognitive impairment and early Alzheimer’s disease. J Neurosci Res 85:3036–3040. https://doi.org/10.1002/jnr.21346
Lovell MA, Xiong S, Markesbery WR, Lynn BC (2005) Quantitative proteomic analysis of mitochondria from primary neuron cultures treated with amyloid beta peptide. Neurochem Res 30:113–122. https://doi.org/10.1007/s11064-004-9692-5
Luissint A-C, Artus C, Glacial F et al (2012) Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9:23. https://doi.org/10.1186/2045-8118-9-23
Leite DM, Seifi M, Ruiz-Perez L et al (2022) Syndapin-2 mediated transcytosis of amyloid-β across the blood–brain barrier. Brain Commun 4:fcac039. https://doi.org/10.1093/braincomms/fcac039
MA Q-L, Harris-White ME, Ubeda OJ et al (2007a) Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer’s models. J Neurochem 103:1594–1607. https://doi.org/10.1111/j.1471-4159.2007.04869.x
Ma W, Lee SE, Guo J et al (2007b) RAGE ligand upregulation of VEGF secretion in ARPE-19 cells. Invest Ophthalmol Vis Sci 48(3):1355–1361. https://doi.org/10.1167/iovs.06-0738
Mackic JB, Stins M, McComb JG et al (1998) Human blood-brain barrier receptors for Alzheimer's amyloid-beta 1- 40. Asymmetrical binding, endocytosis, and transcytosisat the apical side of brain microvascular endothelial cellmonolayer. J Clin Invest 102(4):734–743. https://doi.org/10.1172/JCI2029
Malik P, Kumar Mukherjee T (2022) Immunological methods for the determination of AGE-RAGE axis generated glutathionylated and carbonylated proteins as oxidative stress markers. Methods 203:354–363. https://doi.org/10.1016/j.ymeth.2022.01.011
Matsumoto S, Yoshida T, Murata H et al (2008) Solution structure of the variable-type domain of the receptor for advanced glycation end products: new insight into AGE-RAGE interaction. Biochemistry 47:12299–12311. https://doi.org/10.1021/bi800910v
McCormack JG, Denton RM (1979) The effects of calcium ions and adenine nucleotides on the activity of pig heart 2-oxoglutarate dehydrogenase complex. Biochem J 180:533–544. https://doi.org/10.1042/bj1800533
McCormack JG, Halestrap AP, Denton RM (1990) Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70:391–425. https://doi.org/10.1152/physrev.1990.70.2.391
Mertsch K, Blasig I, Grune T (2001) 4-Hydroxynonenal impairs the permeability of an in vitro rat blood-brain barrier. Neurosci Lett 314:135–138. https://doi.org/10.1016/s0304-3940(01)02299-6
Meyer-Luehmann M, Coomaraswamy J, Bolmont T et al (2006) Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 313:1781–1784. https://doi.org/10.1126/science.1131864
Mieyal JJ, Gallogly MM, Qanungo S et al (2008) Molecular mechanisms and clinical implications of reversible protein S-glutathionylation. Antioxid Redox Signal 10:1941–1988. https://doi.org/10.1089/ars.2008.2089
Miller AA, Drummond GR, Schmidt HHHW, Sobey CG (2005) NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res 97:1055–1062. https://doi.org/10.1161/01.RES.0000189301.10217.87
Mitkevich VA, Petrushanko IY, Yegorov YE et al (2013) Isomerization of Asp7 leads to increased toxic effect of amyloid-β42 on human neuronal cells. Cell Death Dis 4:e939. https://doi.org/10.1038/cddis.2013.492
Mondragón-Rodríguez S, Perry G, Zhu X, Boehm J (2012) Amyloid Beta and tau proteins as therapeutic targets for Alzheimer’s disease treatment: rethinking the current strategy. Int J Alzheimers Dis 2012:630182. https://doi.org/10.1155/2012/630182
Monro OR, Mackic JB, Yamada S et al (2002) Substitution at codon 22 reduces clearance of Alzheimer’s amyloid-β peptide from the cerebrospinal fluid and prevents its transport from the central nervous system into blood. Neurobiol Aging 23:405–412. https://doi.org/10.1016/S0197-4580(01)00317-7
Montagne A, Zhao Z, Zlokovic BV (2017) Alzheimer’s disease: a matter of blood–brain barrier dysfunction? J Exp Med 214:3151–3169. https://doi.org/10.1084/jem.20171406
Musiek ES, Holtzman DM (2015) Three dimensions of the amyloid hypothesis: time, space, and “Wingmen”. Nat. Neurosci 18:800–806. https://doi.org/10.1038/nn.4018
Neeper M, Schmidt AM, Brett J et al (1992) Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 267:14998–15004
Newman SF, Sultana R, Perluigi M et al (2007) An increase in S-glutathionylated proteins in the Alzheimer’s disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85:1506–1514. https://doi.org/10.1002/jnr.21275
Onyango IG, Tuttle JB, Bennett JP Jr (2005) Altered intra-cellular signaling and reduced viability of Alzheimer’s disease neuronal cybrids is reproduced by β-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol. Cell Neurosci. 29:333–343. https://doi.org/10.1016/j.mcn.2005.02.012
Ojakäär T, Koychev I (2021) Secondary prevention of dementia: combining risk factors and scalable screening technology. Front Neurol 12:772836. https://doi.org/10.3389/fneur.2021.772836
Origl N, Arancio O, Domenici L, Yan SS (2009) MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother 9(11):1635–1645. https://doi.org/10.1586/ern.09.107
Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 4:552–565. https://doi.org/10.1038/nrm1150
Pagani L, Eckert A (2011) Amyloid-Beta interaction with mitochondria. Int J Alzheimers Dis 2011:925050. https://doi.org/10.4061/2011/925050
Park L, Anrather J, Forster C et al (2004) Abeta-induced vascular oxidative stress and attenuation of functional hyperemia in mouse somatosensory cortex. J Cereb Blood Flow Metab 24:334–342. https://doi.org/10.1097/01.WCB.0000105800.49957.1E
Park L, Anrather J, Zhou P et al (2005) NADPH-oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta peptide. J Neurosci 25:1769–1777. https://doi.org/10.1523/JNEUROSCI.5207-04.2005
Park L, Anrather J, Girouard H et al (2007) Nox2-derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab 27:1908–1918. https://doi.org/10.1038/sj.jcbfm.9600491
Park H, Adsit FG, Boyington JC (2010) The 1.5 Å crystal structure of human receptor for advanced glycation endproducts (RAGE) ectodomains reveals unique features determining ligand binding. J Biol Chem 285:40762–40770. https://doi.org/10.1074/jbc.M110.169276
Parker WD, Filley CM, Parks JK (1990) Cytochrome oxidase deficiency in Alzheimer’s disease. Neurology 40:1302–1303. https://doi.org/10.1212/wnl.40.8.1302
Parker WD, Parks J, Filley CM, Kleinschmidt-DeMasters BK (1994) Electron transport chain defects in Alzheimer’s disease brain. Neurology 44:1090–1096. https://doi.org/10.1212/wnl.44.6.1090
Patterson BW, Elbert DL, Mawuenyega KG et al (2015) Age and amyloid effects on human central nervous system amyloid-beta kinetics. Ann. Neurol 78:439–453. https://doi.org/10.1002/ana.24454
Paudel YN, Angelopoulou E, Piperi C et al (2020) Revisiting the impact of neurodegenerative proteins in epilepsy: focus on alpha-synuclein, beta-amyloid, and tau. Biology (Basel) 9:E122. https://doi.org/10.3390/biology9060122
Peterson C, Goldman JE (1986) Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A 83:2758–2762. https://doi.org/10.1073/pnas.83.8.2758
Petrovskaya AV, Tverskoi AM, Barykin EP, Varshavskaya KB, Dalina AA, Mitkevich VA, Makarov AA, Petrushanko IY (2022) Distinct effects of beta-amyloid, its isomerized and phosphorylated forms on the redox status and mitochondrial functioning of the blood-brain barrier endothelium. Int J Mol Sci 24(1):183. https://doi.org/10.3390/ijms24010183
Petrushanko IY, Mitkevich VA, Anashkina AA et al (2016) Direct interaction of beta-amyloid with Na,K-ATPase as a putative regulator of the enzyme function. Sci Rep 6:27738. https://doi.org/10.1038/srep27738
Petrushanko IY, Tverskoi AM, Barykin EP, Petrovskaya AV, Strelkova MA, Leonova OG, Anashkina AA, Tolstova AP, Adzhubei AA, Bogdanova AY, Makarov AA, Mitkevich VA (2022) Na,K-ATPase acts as a beta-amyloid receptor triggering src kinase activation. Cells 11:2753. https://doi.org/10.3390/cells11172753
Pocernich CB, Lange MLB, Sultana R, Butterfield DA (2011) Nutritional approaches to modulate oxidative stress in Alzheimer’s disease. Curr Alzheimer Res 8:452–469. https://doi.org/10.2174/156720511796391908
Preston JE, Hipkiss AR, Himsworth DT et al (1998) Toxic effects of beta-amyloid(25-35) on immortalised rat brain endothelial cell: protection by carnosine, homocarnosine and beta-alanine. Neurosci Lett 242:105–108. https://doi.org/10.1016/s0304-3940(98)00058-5
Qu J, Nakamura T, Cao G et al (2011) S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta-amyloid peptide. Proc Natl Acad Sci U S A 108:14330–14335. https://doi.org/10.1073/pnas.1105172108
Quintana DD, Garcia JA, Anantula Y et al (2020) Amyloid-β causes mitochondrial dysfunction via a Ca2+-driven upregulation of oxidative phosphorylation and superoxide production in cerebrovascular endothelial cells. J Alzheimers Dis 75:119–138. https://doi.org/10.3233/JAD-190964
Ramasamy R, Yan SF, Schmidt AM (2012) Advanced glycation endproducts: from precursors to RAGE: round and round we go. Amino Acids 42:1151–1161. https://doi.org/10.1007/s00726-010-0773-2
Roberts KF, Elbert DL, Kasten TP et al (2014) Amyloid-β efflux from the central nervous system into the plasma. Ann Neurol 76:837–844. https://doi.org/10.1002/ana.24270
Roher AE, Chaney MO, Kuo YM et al (1996) Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer’s disease. J Biol Chem 271:20631–20635. https://doi.org/10.1074/jbc.271.34.20631
Rombouts SARB, Goekoop R, Stam CJ et al (2005) Delayed rather than decreased BOLD response as a marker for early Alzheimer’s disease. Neuroimage 26:1078–1085. https://doi.org/10.1016/j.neuroimage.2005.03.022
Rouhiainen A, Kuja-Panula J, Tumova S, Rauvala H (2013) RAGE-mediated cell signaling. Methods Mol Biol 963:239–263. https://doi.org/10.1007/978-1-62703-230-8_15
Sanz-Blasco S, Valero RA, Rodríguez-Crespo I et al (2008) Mitochondrial Ca2+ overload underlies Abeta oligomers neurotoxicity providing an unexpected mechanism of neuroprotection by NSAIDs. PLoS One 3:e2718. https://doi.org/10.1371/journal.pone.0002718
Saraiva AA, Borges MM, Madeira MD et al (1985) Mitochondrial abnormalities in cortical dendrites from patients with Alzheimer’s disease. J Submicrosc Cytol 17:459–464
Schafer FQ, Buettner GR (2001) Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191–1212. https://doi.org/10.1016/s0891-5849(01)00480-4
Schmidt AM, Sahagan B, Nelson RB et al (2009) The role of RAGE in amyloid-beta peptide-mediated pathology in Alzheimer’s disease. Curr Opin Investig Drugs 10:672–680
Schreibelt G, Kooij G, Reijerkerk A et al (2007) Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling. FASEB J 21:3666–3676. https://doi.org/10.1096/fj.07-8329com
Schwartz MP, Matouschek A (1999) The dimensions of the protein import channels in the outer and inner mitochondrial membranes. Proc Natl Acad Sci U S A 96:13086–13090. https://doi.org/10.1073/pnas.96.23.13086
Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8:595–608. https://doi.org/10.15252/emmm.201606210
Sevillano N, Girón MD, Salido M et al (2009) Internalization of the receptor for advanced glycation end products (RAGE) is required to mediate intracellular responses. J Biochem 145:21–30. https://doi.org/10.1093/jb/mvn137
Shah K, Lahiri DK (2014) Cdk5 activity in the brain - multiple paths of regulation. J Cell Sci 127:2391–2400. https://doi.org/10.1242/jcs.147553
Sharda N, Ahlschwede KM, Curran GL et al (2021) Distinct uptake kinetics of Alzheimer disease amyloid-β 40 and 42 at the blood-brain barrier endothelium. J Pharmacol Exp Ther 376:482–490. https://doi.org/10.1124/jpet.120.000086
Shibata M, Yamada S, Kumar SR et al (2000) Clearance of Alzheimer’s amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 106:1489–1499. https://doi.org/10.1172/JCI10498
Simöes Da Gama С, Morin-Brureau M (2022) Study of BBB dysregulation in neuropathogenicity using integrative human model of blood–brain barrier. Front Cell Neurosci. 16:863836. https://doi.org/10.3389/fncel.2022.863836
Smeyne M, Smeyne RJ (2013) Glutathione metabolism and Parkinson’s disease. Free Radic Biol Med 62:13–25. https://doi.org/10.1016/j.freeradbiomed.2013.05.001
Solito R, Corti F, Chen C-H et al (2013) Mitochondrial aldehyde dehydrogenase-2 activation prevents β-amyloid-induced endothelial cell dysfunction and restores angiogenesis. J Cell Sci 126:1952–1961. https://doi.org/10.1242/jcs.117184
Son M, Oh S, Park H et al (2017) Protection against RAGE-mediated neuronal cell death by sRAGE-secreting human mesenchymal stem cells in 5xFAD transgenic mouse model. Brain Behav Immun 66:347–358. https://doi.org/10.1016/j.bbi.2017.07.158
Stamenković S, Pavićević A, Mojović M et al (2017) In vivo EPR pharmacokinetic evaluation of the redox status and the blood brain barrier permeability in the SOD1G93A ALS rat model. Free Radic Biol Med 108:258–269. https://doi.org/10.1016/j.freeradbiomed.2017.03.034
Stone NL, England TJ, O’Sullivan SE (2019) A novel transwell blood brain barrier model using primary human cells. Front Cell Neurosci 13:230. https://doi.org/10.3389/fncel.2019.00230
Sturchler E, Galichet A, Weibel M et al (2008) Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci 28:5149–5158. https://doi.org/10.1523/JNEUROSCI.4878-07.2008
Sumpter PQ, Mann DM, Davies CA et al (1986) An ultrastructural analysis of the effects of accumulation of neurofibrillary tangle in pyramidal neurons of the cerebral cortex in Alzheimer’s disease. Neuropathol Appl Neurobiol 12:305–319. https://doi.org/10.1111/j.1365-2990.1986.tb00142.x
Tai LM, Holloway KA, Male DK et al (2010) Amyloid-beta-induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. J Cell Mol Med 14:1101–1112. https://doi.org/10.1111/j.1582-4934.2009.00717.x
Tayarani I, Chaudiere J, Lefauconnier JM, Bourre JM (1987) Enzymatic protection against peroxidative damage in isolated brain capillaries. J Neurochem 48:1399–1402. https://doi.org/10.1111/j.1471-4159.1987.tb05677.x
Tian X, Leite DM, Scarpa E et al (2020) On the shuttling across the blood-brain barrier via tubule formation: mechanism and cargo avidity bias. Sci Adv 6:eabc4397. https://doi.org/10.1126/sciadv.abc4397
Tolstova AP, Adzhubei AA, Mitkevich VA, Petrushanko IY, Makarov AA (2022) Docking and molecular dynamics-based identification of interaction between various beta-amyloid isoforms and RAGE receptor. Int J Mol Sci 23(19):11816. https://doi.org/10.3390/ijms231911816
Tramutola A, Lanzillotta C, Perluigi M, Butterfield DA (2017) Oxidative stress, protein modification and Alzheimer disease. Brain Res Bull 133:88–96. https://doi.org/10.1016/j.brainresbull.2016.06.005
Udeh-Momoh C, Zheng B, Sandebring-Matton A et al (2021) Blood derived amyloid biomarkers for Alzheimer’s disease prevention. J Prev Alzheimers Dis 9(1):12–21. https://doi.org/10.14283/jpad.2021.70
Ujiie M, Dickstein DL, Carlow DA, Jefferies WA (2003) Blood–brain barrier permeability precedes senile plaque formation in an Alzheimer disease model. Microcirculation 10:463–470. https://doi.org/10.1080/mic.10.6.463.470
Versele R, Corsi M, Fuso A et al (2020) Ketone bodies promote amyloid-β1-40 clearance in a human in vitro blood-brain barrier model. Int J Mol Sci 21:E934. https://doi.org/10.3390/ijms21030934
Vesković A, Nakarada Đ, Pavićević A et al (2021) In vivo/ex vivo EPR investigation of the brain redox status and blood--brain barrier integrity in the 5xFAD mouse model of Alzheimer’s disease. Curr Alzheimer Res. https://doi.org/10.2174/1567205018666210324121156
Villaseñor R, Lampe J, Schwaninger M, Collin L (2019) Intracellular transport and regulation of transcytosis across the blood-brain barrier. Cell Mol Life Sci 76(6):1081–1092. https://doi.org/10.1007/s00018-018-2982-x
Volpina OM, Koroev DO, Volkova TD et al (2015) Fragment of receptor for advanced glycation end products improves memory state in a model of Alzheimer’s disease. Bioorg Khim 41:709–716. https://doi.org/10.1134/s1068162015060187
Volpina OM, Samokhin AN, Koroev DO et al (2018) Synthetic fragment of receptor for advanced glycation end products prevents memory loss and protects brain neurons in olfactory bulbectomized mice. J Alzheimers Dis 61:1061–1076. https://doi.org/10.3233/JAD-170483
Wan W, Chen H, Li Y (2014) The potential mechanisms of Aβ-receptor for advanced glycation end-products interaction disrupting tight junctions of the blood-brain barrier in Alzheimer’s disease. Int J Neurosci 124:75–81. https://doi.org/10.3109/00207454.2013.825258
Wan W, Cao L, Liu L et al (2015) Aβ(1-42) oligomer-induced leakage in an in vitro blood-brain barrier model is associated with up-regulation of RAGE and metalloproteinases, and down-regulation of tight junction scaffold proteins. J Neurochem 134:382–393. https://doi.org/10.1111/jnc.13122
Wang Z, Wang B, Yang L et al (2009) Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci 29:10788–10801. https://doi.org/10.1523/JNEUROSCI.2132-09.2009
Wang Z, Sharda N, Curran GL et al (2021) Semimechanistic population pharmacokinetic modeling to investigate amyloid beta trafficking and accumulation at the BBB endothelium. Mol Pharm 18:4148–4161. https://doi.org/10.1021/acs.molpharmaceut.1c00549
Watson PM, Anderson JM, Vanltallie CM, Doctrow SR (1991) The tight-junction-specific protein ZO-1 is a component of the human and rat blood-brain barriers. Neurosci Lett 129:6–10. https://doi.org/10.1016/0304-3940(91)90708-2
Weksler B, Romero IA, Couraud P-O (2013) The hCMEC/D3 cell line as a model of the human blood brain barrier. Fluids Barriers CNS 10:16. https://doi.org/10.1186/2045-8118-10-16
Won J-S, Kim J, Annamalai B et al (2013) Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion. J Alzheimers Dis 34:621–635. https://doi.org/10.3233/JAD-121786
Xiang Y, Bu X-L, Liu Y-H et al (2015) Physiological amyloid-beta clearance in the periphery and its therapeutic potential for Alzheimer’s disease. Acta Neuropathol 130:487–499. https://doi.org/10.1007/s00401-015-1477-1
Xue J, Rai V, Singer D et al (2011) Advanced glycation end product recognition by the receptor for AGEs. Structure 19:722–732. https://doi.org/10.1016/j.str.2011.02.013
Xue J, Ray R, Singer D et al (2014) The receptor for advanced glycation end products (RAGE) specifically recognizes methylglyoxal-derived AGEs. Biochemistry 53:3327–3335. https://doi.org/10.1021/bi500046t
Yan SD, Chen X, Fu J et al (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer’s disease. Nature 382:685–691. https://doi.org/10.1038/382685a0
Yatime L, Andersen GR (2013) Structural insights into the oligomerization mode of the human receptor for advanced glycation end-products. FEBS J 280:6556–6568. https://doi.org/10.1111/febs.12556
Zatsepina OG, Kechko OI, Mitkevich VA et al (2018) Amyloid-β with isomerized Asp7 cytotoxicity is coupled to protein phosphorylation. Sci Rep 8:3518. https://doi.org/10.1038/s41598-018-21815-x
Zhang Y, Xu H (2007) Molecular and cellular mechanisms for Alzheimer’s disease: understanding APP metabolism. Curr Mol Med 7:687–696. https://doi.org/10.2174/156652407782564462
Zhou AL, Sharda N, Sarma VV et al (2022) Age-dependent changes in the plasma and brain pharmacokinetics of amyloid-β peptides and insulin. J Alzheimer’s Dis 85:1031–1044. https://doi.org/10.3233/JAD-215128
Zhu D, Su Y, Fu B, Xu H (2018) Magnesium reduces blood-brain barrier permeability and regulates amyloid-β transcytosis. Mol Neurobiol 55:7118–7131. https://doi.org/10.1007/s12035-018-0896-0
Zong H, Madden A, Ward M et al (2010) Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction. J. Biol. Chem. 285:23137–23146. https://doi.org/10.1074/jbc.M110.133827
Funding
This research was funded by Russian Science Foundation (Grant No. #19-74-30007).
Author information
Authors and Affiliations
Contributions
The first draft of the manuscript was written by I.Yu.P. I.Yu.P., V.A.M., and A.A.M. commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval
Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors.
Consent to participate
Not applicable
Consent for publication
Not applicable
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Petrushanko, I.Y., Mitkevich, V.A. & Makarov, A.A. Effect of β-amyloid on blood-brain barrier properties and function. Biophys Rev 15, 183–197 (2023). https://doi.org/10.1007/s12551-023-01052-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12551-023-01052-x